The mitochondrial H+-ATP synthase and the lipogenic switch New core components of metabolic reprogramming in induced pluripotent stem (iPS) cells

Cell Cycle

Volumn 12, Issue 2, 2013, Pages 207-218

  Vazquez Martin, Alejandro ^a,b   Corominas Faja, Bruna ^a,b   Cufi, Sílvia ^a,b   Vellon, Luciano ^c   Oliveras Ferraros, Cristina ^a,b   Menendez, Octavio J ^a,b   Joven, Jorge ^d   Lupu, Ruth ^e   Menendez, Javier A ^a,b  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^c Fundacion Inbiomed   (Spain)

^d INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

^e MAYO CLINIC CANCER CENTER   (United States)

Author keywords

Acetyl CoA carboxylase; Bioenergetics; Fatty acid synthase; Glycolysis; IF1; IPS cells; Lipogenesis; Mitochondria; SSEA1; Warburg effect

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; FATTY ACID SYNTHASE; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE;

ANIMAL CELL; ARTICLE; CELL DEDIFFERENTIATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; FIBROBLAST; LIPOGENIC SWITCH; MITOCHONDRION; MOUSE; NONHUMAN; NUCLEAR REPROGRAMMING; OXIDATIVE PHOSPHORYLATION; PLURIPOTENT STEM CELL; PROCEDURES CONCERNING CELLS; PROGENY; PROTEIN EXPRESSION;

EID: 84873624215     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.23352     Document Type: Article

References (97)

1. Prigione A, Fauler B, Lurz R, Lehrach H, Adjaye J. The senescence-related mitochondrial/oxidative stress pathway is repressed in human induced pluripotent stem cells. Stem Cells 2010; 28:721- 33; PMID:20201066; http://dx.doi.org/10.1002/stem.404.
2. Suhr ST, Chang EA, Tjong J, Alcasid N, Perkins GA, Goissis MD, et al. Mitochondrial rejuvenation after induced pluripotency. PLoS One 2010; 5:e14095; PMID:21124794; http://dx.doi.org/10.1371/journal.pone.0014095.
3. Prigione A, Adjaye J. Modulation of mitochondrial biogenesis and bioenergetic metabolism upon in vitro and in vivo differentiation of human ES and iPS cells. Int J Dev Biol 2010; 54:1729-41; PMID:21305470; http://dx.doi.org/10.1387/ijdb.103198ap.
4. Varum S, Rodrigues AS, Moura MB, Momcilovic O, Easley CA 4th, Ramalho-Santos J, et al. Energy metabolism in human pluripotent stem cells and their differentiated counterparts. PLoS One 2011; 6:e20914; PMID:21698063; http://dx.doi.org/10.1371/journal.pone.0020914.
5. Prigione A, Lichtner B, Kuhl H, Struys EA, Wamelink M, Lehrach H, et al. Human induced pluripotent stem cells harbor homoplasmic and heteroplasmic mitochondrial DNA mutations while maintaining human embryonic stem cell-like metabolic reprogramming. Stem Cells 2011; 29:1338-48; PMID:21732474.
6. Folmes CD, Nelson TJ, Martinez-Fernandez A, Arrell DK, Lindor JZ, Dzeja PP, et al. Somatic oxidative bioenergetics transitions into pluripotency- dependent glycolysis to facilitate nuclear reprogramming. Cell Metab 2011; 14:264-71; PMID:21803296; http://dx.doi.org/10.1016/j.cmet.2011.06.011.
7. Panopoulos AD, Yanes O, Ruiz S, Kida YS, Diep D, Tautenhahn R, et al. The metabolome of induced pluripotent stem cells reveals metabolic changes occurring in somatic cell reprogramming. Cell Res 2012; 22:168-77; PMID:22064701; http://dx.doi.org/10.1038/cr.2011.177.
8. Menendez JA, Vellon L, Oliveras-Ferraros C, Cufí S, Vazquez-Martin A. mTOR-regulated senescence and autophagy during reprogramming of somatic cells to pluripotency: a roadmap from energy metabolism to stem cell renewal and aging. Cell Cycle 2011; 10:3658-77; PMID:22052357; http://dx.doi.org/10.4161/ cc.10.21.18128.
9. Vazquez-Martin A, Vellon L, Quirós PM, Cufí S, Ruiz de Galarreta E, Oliveras-Ferraros C, et al. Activation of AMP-activated protein kinase (AMPK) provides a metabolic barrier to reprogramming somatic cells into stem cells. Cell Cycle 2012; 11:974- 89; PMID:22333578; http//dx.doi.org/10. 4161/cc.11.5.19450.
10. Hardie DG. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev 2011; 25:1895-908; PMID:21937710; http://dx.doi.org/10.1101/gad.17420111.
11. Hardie DG. Adenosine monophosphate-activated protein kinase: a central regulator of metabolism with roles in diabetes, cancer, and viral infection. Cold Spring Harb Symp Quant Biol 2011; 76:155- 64; PMID:22071265; http://dx.doi.org/10.1101/sqb.2011.76.010819.
12. Hardie DG. Sensing of energy and nutrients by AMP-activated protein kinase. Am J Clin Nutr 2011; 93:891S-6; PMID:21325438; http://dx.doi.org/10. 3945/ajcn.110.001925.
13. Phoenix KN, Devarakonda CV, Fox MM, Stevens LE, Claffey KP. AMPKα2 suppresses murine embryonic fibroblast transformation and tumorigenesis. Genes Cancer 2012; 3:51-62; PMID:22893790; http://dx.doi.org/10.1177/1947601912452883.
14. Cuezva JM, Sánchez-Aragó M, Sala S, Blanco-Rivero A, Ortega AD. A message emerging from development: the repression of mitochondrial beta-F1- ATPase expression in cancer. J Bioenerg Biomembr 2007; 39:259-65; PMID:17712532; http://dx.doi.org/10.1007/s10863-007-9087-9.
15. Sánchez-Aragó M, Formentini L, Cuezva JM. Mitochondria-Mediated Energy Adaption in Cancer: The H(+)-ATP Synthase-Geared Switch of Metabolism in Human Tumors. Antioxid Redox Signal 2012; In press; PMID:22901241; http://dx.doi.org/10.1089/ars.2012.4883.
16. Sánchez-Cenizo L, Formentini L, Aldea M, Ortega AD, García-Huerta P, Sánchez-Aragó M, et al. Up-regulation of the ATPase inhibitory factor 1 (IF1) of the mitochondrial H+-ATP synthase in human tumors mediates the metabolic shift of cancer cells to a Warburg phenotype. J Biol Chem 2010; 285:25308-13; PMID:20538613; http://dx.doi.org/10. 1074/jbc.M110.146480.
17. Sánchez-Aragó M, Formentini L, García- Bermúdez J, Cuezva JM. IF1 reprograms energy metabolism and signals the oncogenic phenotype in cancer. Cell Cycle 2012; 11:2963-4; PMID:22871729; http://dx.doi.org/10.4161/cc.21387.
18. Sánchez-Aragó M, Chamorro M, Cuezva JM. Selection of cancer cells with repressed mitochondria triggers colon cancer progression. Carcinogenesis 2010; 31:567-76; PMID:20080835; http://dx.doi.org/10.1093/carcin/ bgq012.
19. Willers IM, Cuezva JM. Post-transcriptional regulation of the mitochondrial H(+)-ATP synthase: a key regulator of the metabolic phenotype in cancer. Biochim Biophys Acta 2011; 1807:543-51; PMID:21035425; http://dx.doi.org/10.1016/j.bbabio.2010.10.016.
20. Ortega AD, Sala S, Espinosa E, González-Barón M, Cuezva JM. HuR and the bioenergetic signature of breast cancer: a low tumor expression of the RNA-binding protein predicts a higher risk of disease recurrence. Carcinogenesis 2008; 29:2053-61; PMID:18687667; http://dx.doi.org/10.1093/ carcin/bgn185.
21. Ortega AD, Willers IM, Sala S, Cuezva JM. Human G3BP1 interacts with beta-F1-ATPase mRNA and inhibits its translation. J Cell Sci 2010; 123:2685- 96; PMID:20663914; http://dx.doi.org/10.1242/jcs.065920.
22. Li RJ, Zhang GS, Chen YH, Zhu JF, Lu QJ, Gong FJ, et al. Down-regulation of mitochondrial ATPase by hypermethylation mechanism in chronic myeloid leukemia is associated with multidrug resistance. Ann Oncol 2010; 21:1506-14; PMID:20038517; http://dx.doi.org/10.1093/annonc/mdp569.
23. Faccenda D, Campanella M. Molecular Regulation of the Mitochondrial F(1)F(o)-ATPsynthase: Physiological and Pathological Significance of the Inhibitory Factor 1 (IF(1)). Int J Cell Biol 2012; 2012:367934; PMID:22966230; http://dx.doi.org/10.1155/2012/367934.
24. Brambrink T, Foreman R, Welstead GG, Lengner CJ, Wernig M, Suh H, et al. Sequential expression of pluripotency markers during direct reprogramming of mouse somatic cells. Cell Stem Cell 2008; 2:151- 9; PMID:18371436; http://dx.doi.org/10.1016/j.stem.2008.01.004.
25. Cox JL, Rizzino A. Induced pluripotent stem cells: what lies beyond the paradigm shift. Exp Biol Med (Maywood) 2010; 235:148-58; PMID:20404029; http://dx.doi.org/10.1258/ebm.2009.009267.
26. Kukidome D, Nishikawa T, Sonoda K, Imoto K, Fujisawa K, Yano M, et al. Activation of AMPactivated protein kinase reduces hyperglycemiainduced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. Diabetes 2006; 55:120-7; PMID:16380484; http://dx.doi.org/10.2337/diabetes.55.01.06.db05-0943.
27. Beeson CC, Beeson GC, Schnellmann RG. A highthroughput respirometric assay for mitochondrial biogenesis and toxicity. Anal Biochem 2010; 404:75- 81; PMID:20465991; http://dx.doi.org/10.1016/j.ab.2010.04.040.
28. Oliveras-Ferraros C, Cufí S, Vazquez-Martin A, Menendez OJ, Bosch-Barrera J, Martin-Castillo B, et al. Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation. Cell Cycle 2012; 11:865- 70; PMID:22333588; http://dx.doi.org/ 10.4161/cc.11.5.19252.
29. Gomes LC, Di Benedetto G, Scorrano L. During autophagy mitochondria elongate, are spared from degradation and sustain cell viability. Nat Cell Biol 2011; 13:589-98; PMID:21478857; http://dx.doi. org/10.1038/ncb2220.
30. Mihaylova MM, Shaw RJ. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol 2011; 13:1016-23; PMID:21892142; http://dx.doi.org/10.1038/ncb2329.
31. Vazquez-Martin A, Cufi S, Corominas-Faja B, Oliveras-Ferraros C, Vellon L, Menendez JA. Mitochondrial fusion by pharmacological manipulation impedes somatic cell reprogramming to pluripotency: new insight into the role of mitophagy in cell stemness. Aging (Albany NY) 2012; 4:393-401; PMID:22713507.
32. Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev 2009; 23:537-48; PMID:19270154; http://dx.doi.org/10.1101/gad.1756509.
33. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324:1029-33; PMID:19460998; http://dx.doi.org/10.1126/science.1160809.
34. Israël M, Schwartz L. The metabolic advantage of tumor cells. Mol Cancer 2011; 10:70; PMID:21649891; http://dx.doi.org/10.1186/1476-4598-10-70.
35. Furuta E, Okuda H, Kobayashi A, Watabe K. Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochim Biophys Acta 2010; 1805:141-52; PMID:20122995.
36. Menendez JA. Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth: molecular mechanisms and therapeutic perspectives. Biochim Biophys Acta 2010; 1801:381-91; PMID:19782152; http://dx.doi.org/10.1016/j.bbalip.2009.09.005.
37. Menendez JA, Lupu R. Fatty acid synthase-catalyzed de novo fatty acid biosynthesis: from anabolicenergy- storage pathway in normal tissues to jack-ofall- trades in cancer cells. Arch Immunol Ther Exp (Warsz) 2004; 52:414-26; PMID:15577743.
38. Menendez JA, Lupu R, Colomer R. Targeting fatty acid synthase: potential for therapeutic intervention in her-2/neu-overexpressing breast cancer. Drug News Perspect 2005; 18:375-85; PMID:16247515; http://dx.doi.org/10.1358/dnp. 2005.18.6.927929.
39. Menendez JA, Lupu R. Oncogenic properties of the endogenous fatty acid metabolism: molecular pathology of fatty acid synthase in cancer cells. Curr Opin Clin Nutr Metab Care 2006; 9:346- 57; PMID:16778562; http://dx.doi.org/10. 1097/01.mco.0000232893.21050.15.
40. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007; 7:763-77; PMID:17882277; http://dx.doi.org/10.1038/nrc2222.
41. Menendez JA, Vazquez-Martin A, Ortega FJ, Fernandez-Real JM. Fatty acid synthase: association with insulin resistance, type 2 diabetes, and cancer. Clin Chem 2009; 55:425-38; PMID:19181734; http://dx.doi.org/10.1373/clinchem.2008. 115352.
42. Menendez JA, Vellon L, Mehmi I, Oza BP, Ropero S, Colomer R, et al. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci USA 2004; 101:10715-20; PMID:15235125; http://dx.doi.org/10.1073/pnas.0403390101.
43. Menendez JA, Mehmi I, Verma VA, Teng PK, Lupu R. Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation. Mol Carcinog 2004; 41:164- 78; PMID:15390078; http://dx.doi.org/10.1002/mc.20054.
44. Menendez JA, Oza BP, Atlas E, Verma VA, Mehmi I, Lupu R. Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifeninduced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells. Oncogene 2004; 23:4945-58; PMID:15094777; http://dx.doi.org/10.1038/sj.onc.1207476.
45. Menendez JA, Vellon L, Colomer R, Lupu R. Pharmacological and small interference RNAmediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity. Int J Cancer 2005; 115:19-35; PMID:15657900; http://dx.doi.org/10.1002/ijc.20754.
46. Vazquez-Martin A, Colomer R, Brunet J, Lupu R, Menendez JA. Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. Cell Prolif 2008; 41:59-85; PMID:18211286; http://dx.doi. org/10.1111/j.1365-2184.2007.00498.x.
47. Rysman E, Brusselmans K, Scheys K, Timmermans L, Derua R, Munck S, et al. De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res 2010; 70:8117-26; PMID:20876798; http://dx.doi.org/10.1158/0008-5472.CAN-09- 3871.
48. Swinnen JV, Brusselmans K, Verhoeven G. Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care 2006; 9:358- 65; PMID:16778563; http://dx.doi.org/10.1097/01.mco.0000232894.28674.30.
49. Beckers A, Organe S, Timmermans L, Scheys K, Peeters A, Brusselmans K, et al. Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. Cancer Res 2007; 67:8180-7; PMID:17804731; http://dx.doi.org/10.1158/0008-5472.CAN-07-0389.
50. Kuhajda FP. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 2000; 16:202-8; PMID:10705076; http://dx.doi.org/10.1016/S0899-9007(99)00266-X.
51. Kuhajda FP. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 2006; 66:5977-80; PMID:16778164; http://dx.doi.org/10.1158/ 0008-5472.CAN-05-4673.
52. Kourtidis A, Srinivasaiah R, Carkner RD, Brosnan MJ, Conklin DS. Peroxisome proliferator-activated receptor-gamma protects ERBB2-positive breast cancer cells from palmitate toxicity. Breast Cancer Res 2009; 11:R16; PMID:19298655; http://dx.doi.org/10.1186/bcr2240.
53. Kourtidis A, Jain R, Carkner RD, Eifert C, Brosnan MJ, Conklin DS. An RNA interference screen identifies metabolic regulators NR1D1 and PBP as novel survival factors for breast cancer cells with the ERBB2 signature. Cancer Res 2010; 70:1783-92; PMID:20160030; http://dx.doi.org/10.1158/0008-5472.CAN-09- 1550.
54. DiDonato D, Brasaemle DL. Fixation methods for the study of lipid droplets by immunofluorescence microscopy. J Histochem Cytochem 2003; 51:773-80; PMID:12754288; http://dx.doi.org/10.1177/002215540305100608.
55. Grandl M, Schmitz G. Fluorescent high-content imaging allows the discrimination and quantitation of E-LDL-induced lipid droplets and Ox-LDLgenerated phospholipidosis in human macrophages. Cytometry A 2010; 77:231-42; PMID:20014301.
56. Vazquez-Martin A, Ortega-Delgado FJ, Fernandez- Real JM, Menendez JA. The tyrosine kinase receptor HER2 (erbB-2): from oncogenesis to adipogenesis. J Cell Biochem 2008; 105:1147-52; PMID:18814184; http://dx.doi.org/10.1002/jcb. 21917.
57. Wright HM, Clish CB, Mikami T, Hauser S, Yanagi K, Hiramatsu R, et al. A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation. J Biol Chem 2000; 275:1873-7; PMID:10636887; http://dx.doi.org/10.1074/jbc.275.3.1873.
58. Bishop-Bailey D, Hla T, Warner TD. Bisphenol A diglycidyl ether (BADGE) is a PPARgamma agonist in an ECV304 cell line. Br J Pharmacol 2000; 131:651-4; PMID:11030710; http://dx.doi.org/10.1038/sj.bjp.0703628.
59. Mo C, Chearwae W, Bright JJ. PPARgamma regulates LIF-induced growth and self-renewal of mouse ES cells through Tyk2-Stat3 pathway. Cell Signal 2010; 22:495-500; PMID:19922793; http://dx.doi.org/10.1016/j.cellsig.2009.11.003.
60. Inazawa Y, Nakatsu M, Yasugi E, Saeki K, Yuo A. Lipid droplet formation in human myeloid NB4 cells stimulated by all trans retinoic acid and granulocyte colony-stimulating factor: possible involvement of peroxisome proliferator-activated receptor gamma. Cell Struct Funct 2003; 28:487-93; PMID:14745140; http://dx.doi.org/10.1247/csf.28.487.
61. Yun JW, Shin ES, Cho SY, Kim SH, Kim CW, Lee TR, et al. The effects of BADGE and caffeine on the time-course response of adiponectin and lipid oxidative enzymes in high fat diet-fed C57BL/6J mice: correlation with reduced adiposity and steatosis. Exp Anim 2008; 57:461-9; PMID:18946183; http://dx.doi.org/10.1538/expanim.57.461.
62. Kuhajda FP, Pizer ES, Li JN, Mani NS, Frehywot GL, Townsend CA. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci USA 2000; 97:3450-4; PMID:10716717; http://dx.doi.org/10.1073/pnas.97.7. 3450.
63. Pizer ES, Thupari J, Han WF, Pinn ML, Chrest FJ, Frehywot GL, et al. Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res 2000; 60:213-8; PMID:10667561.
64. Kuhajda FP, Landree LE, Ronnett GV. The connections between C75 and obesity drug-target pathways. Trends Pharmacol Sci 2005; 26:541- 4; PMID:16169094; http://dx.doi.org/10.1016/j.tips.2005.09.002.
65. Lupu R, Menendez JA. Pharmacological inhibitors of Fatty Acid Synthase (FASN)-catalyzed endogenous fatty acid biogenesis: a new family of anticancer agents? Curr Pharm Biotechnol 2006; 7:483-93; PMID:17168665; http://dx.doi.org/10.2174/138920106779116928.
66. Bentebibel A, Sebastián D, Herrero L, López-Viñas E, Serra D, Asins G, et al. Novel effect of C75 on carnitine palmitoyltransferase I activity and palmitate oxidation. Biochemistry 2006; 45:4339- 50; PMID:16584169; http://dx.doi.org/10.1021/bi052186q.
67. Gerth K, Bedorf N, Irschik H, Höfle G, Reichenbach H. The soraphens: a family of novel antifungal compounds from Sorangium cellulosum (Myxobacteria). I. Soraphen A1 alpha: fermentation, isolation, biological properties. J Antibiot (Tokyo) 1994; 47:23-31; PMID:8119858; http://dx.doi.org/10.7164/antibiotics.47.23.
68. Vahlensieck HF, Pridzun L, Reichenbach H, Hinnen A. Identification of the yeast ACC1 gene product (acetyl-CoA carboxylase) as the target of the polyketide fungicide soraphen A. Curr Genet 1994; 25:95-100; PMID:7916271; http://dx.doi.org/10.1007/BF00309532.
69. Shen Y, Volrath SL, Weatherly SC, Elich TD, Tong L. A mechanism for the potent inhibition of eukaryotic acetyl-coenzyme A carboxylase by soraphen A, a macrocyclic polyketide natural product. Mol Cell 2004; 16:881-91; PMID:15610732; http://dx.doi.org/10.1016/j.molcel.2004.11.034.
70. Beckers A, Organe S, Timmermans L, Scheys K, Peeters A, Brusselmans K, et al. Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. Cancer Res 2007; 67:8180-7; PMID:17804731; http://dx.doi.org/10.1158/0008-5472.CAN-07-0389.
71. Rysman E, Brusselmans K, Scheys K, Timmermans L, Derua R, Munck S, et al. De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res 2010; 70:8117-26; PMID:20876798; http://dx.doi.org/10.1158/0008-5472.CAN-09- 3871.
72. Jump DB, Torres-Gonzalez M, Olson LK. Soraphen A, an inhibitor of acetyl CoA carboxylase activity, interferes with fatty acid elongation. Biochem Pharmacol 2011; 81:649-60; PMID:21184748; http://dx.doi.org/10.1016/j.bcp.2010. 12.014.
73. Brickman JM, Burdon TG. Pluripotency and tumorigenicity. Nat Genet 2002; 32:557-8; PMID:12457185; http://dx.doi.org/10.1038/ng1202-557.
74. Knoepfler PS. Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine. Stem Cells 2009; 27:1050-6; PMID:19415771; http://dx.doi.org/10.1002/stem.37.
75. Blum B, Benvenisty N. The tumorigenicity of human embryonic stem cells. Adv Cancer Res 2008; 100:133-58; PMID:18620095; http://dx.doi.org/10.1016/S0065- 230X(08)00005-5.
76. Ben-David U, Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer 2011; 11:268-77; PMID:21390058; http://dx.doi.org/10.1038/nrc3034.
77. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004; 4:891-9; PMID:15516961; http://dx.doi.org/10.1038/nrc1478.
78. Kondoh H, Lleonart ME, Gil J, Wang J, Degan P, Peters G, et al. Glycolytic enzymes can modulate cellular life span. Cancer Res 2005; 65:177-85; PMID:15665293.
79. Kondoh H, Lleonart ME, Nakashima Y, Yokode M, Tanaka M, Bernard D, et al. A high glycolytic flux supports the proliferative potential of murine embryonic stem cells. Antioxid Redox Signal 2007; 9:293- 9; PMID:17184172; http://dx.doi.org/10.1089/ars.2006.1467.
80. Kondoh H, Lleonart ME, Bernard D, Gil J. Protection from oxidative stress by enhanced glycolysis; a possible mechanism of cellular immortalization. Histol Histopathol 2007; 22:85-90; PMID:17128414.
81. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008; 7:11-20; PMID:18177721; http://dx.doi.org/10.1016/j.cmet.2007.10.002.
82. Kondoh H. Cellular life span and the Warburg effect. Exp Cell Res 2008; 314:1923-8; PMID:18410925; http://dx.doi.org/10.1016/j.yexcr.2008.03.007.
83. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013.
84. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012; 21:297-308; PMID:22439925; http://dx.doi.org/10.1016/j.ccr.2012.02.014.
85. Riggs JW, Barrilleaux BL, Varlakhanova N, Bush KM, Chan V, Knoepfler PS. Induced Pluripotency and Oncogenic Transformation Are Related Processes. Stem Cells Dev 2012; In press; PMID:22998387.
86. Del Barco S, Vazquez-Martin A, Cufí S, Oliveras- Ferraros C, Bosch-Barrera J, Joven J, et al. Metformin: multi-faceted protection against cancer. Oncotarget 2011; 2:896-917; PMID:22203527.
87. Menendez JA, Colomer R, Lupu R. Why does tumor-associated fatty acid synthase (oncogenic antigen- 519) ignore dietary fatty acids? Med Hypotheses 2005; 64:342-9; PMID:15607569; http://dx.doi. org/10.1016/j.mehy.2004.07.022.
88. Folmes CD, Nelson TJ, Terzic A. Energy metabolism in nuclear reprogramming. Biomark Med 2011; 5:715-29; PMID:22103608; http://dx.doi.org/10. 2217/bmm.11.87.
89. Folmes CD, Nelson TJ, Dzeja PP, Terzic A. Energy metabolism plasticity enables stemness programs. Ann N Y Acad Sci 2012; 1254:82-9; PMID:22548573; http://dx.doi.org/10.1111/j.1749-6632.2012.06487.x.
90. Tansey JT, Sztalryd C, Hlavin EM, Kimmel AR, Londos C. The central role of perilipin a in lipid metabolism and adipocyte lipolysis. IUBMB Life 2004; 56:379-85; PMID:15545214; http://dx.doi.org/10.1080/15216540400009968.
91. Brasaemle DL. Thematic review series: adipocyte biology. The perilipin family of structural lipid droplet proteins: stabilization of lipid droplets and control of lipolysis. J Lipid Res 2007; 48:2547- 59; PMID:17878492; http://dx.doi.org/10.1194/jlr.R700014-JLR200.
92. Chen PM, Gombart ZJ, Chen JW. Chloroquine treatment of ARPE-19 cells leads to lysosome dilation and intracellular lipid accumulation: possible implications of lysosomal dysfunction in macular degeneration. Cell Biosci 2011; 1:10; PMID:21711726; http://dx.doi.org/10.1186/2045-3701-1-10.
93. Zhang Y, Yao L, Yu X, Ou J, Hui N, Liu S. A poor imitation of a natural process: A call to reconsider the iPSC engineering technique. Cell Cycle 2012; 11; PMID:23114619; http://dx.doi.org/10.4161/cc.22575.
94. Menendez JA, Vazquez-Martin A. Rejuvenating regeneration: metformin activates endogenous adult stem cells. Cell Cycle 2012; 11:3521-2; PMID:22935702; http://dx.doi.org/10.4161/cc.21878.
95. Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Quirantes R, Segura-Carretero A, Micol V, et al. Metformin lowers the threshold for stress-induced senescence: a role for the microRNA-200 family and miR-205. Cell Cycle 2012; 11:1235-46; PMID:22356767; http://dx.doi.org/10.4161/cc.11.6.19665.
96. Corominas-Faja B, Quirantes-Piné R, Oliveras- Ferraros C, Vazquez-Martin A, Cufí S, Martin- Castillo B, et al. Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs. Aging (Albany NY) 2012; 4:480-98; PMID:22837425.
97. Vazquez-Martin A, Cufí S, Lopez-Bonet E, Corominas-Faja B, Oliveras-Ferraros C, Martin- Castillo B, et al. Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency. Sci Rep 2012; 2:964; PMID:23236586; http://dx.doi.org/10.1038/srep00964.